Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Theravance Biopharma R&D IP, LLC”

252 pharma patents match "Theravance Biopharma R&D IP, LLC" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 252
Index total 30,257
Page 3 / 11

Quick answer

This filtered view shows 252 pharmaceutical patents matching "Theravance Biopharma R&D IP, LLC" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

252 results for “Theravance Biopharma R&D IP, LLC” · 30,257 patents in full index Clear search

  1. US 11254669

    Fused imidazo-piperidine JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  2. US 11254655

    Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

    Theravance Biopharma R&D IP, LLC · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  3. US 11247969

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted
  4. US 11230536

    Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

    Theravance Biopharma R&D IP, LLC · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted
  5. US 11174219

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  6. US 11160800

    Methods of treatment using a JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted
  7. US 11160810

    Fused imidazo-piperidine JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted
  8. US 11155549

    Ester and carbonate pyrimidine compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  9. US 11124502

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  10. US 11110095

    Pyrimidine compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted
  11. US 11033533

    (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

    Theravance Biopharma R&D IP, LLC · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted
  12. US 11008289

    Crystalline freebase forms of a biphenyl compound

    Theravance Biopharma R&D IP, LLC · Granted May 18, 2021 · Expires May 13, 2041

    granted
  13. US 10988470

    Pyrimidine compound as JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Apr 27, 2021 · Expires Apr 22, 2041

    granted
  14. US 10968205

    Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  15. US 10968222

    2-azabicyclo hexane JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  16. US 10961267

    Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease

    Theravance Biopharma R&D IP, LLC · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted
  17. US 10952996

    ALK5 inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  18. US 10954237

    JAK inhibitors containing a 4-membered heterocyclic amide

    Theravance Biopharma R&D IP, LLC · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  19. US 10946009

    Combination dosage form of a mu opioid receptor antagonist and an opioid agent

    Theravance Biopharma R&D IP, LLC · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  20. US 10947254

    Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

    Theravance Biopharma R&D IP, LLC · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  21. US 10946007

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Theravance Biopharma R&D IP, LLC · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  22. US 10946006

    Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

    Theravance Biopharma R&D IP, LLC · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  23. US 10913740

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Theravance Biopharma R&D IP, LLC · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  24. US 10851102

    Imidazole and triazole containing bicyclic compounds as JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted